ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tradipitant

Also written as “Tradipitant”, “VLY-686” and “LY686017”.

Its studies are mostly in Motion Sickness · Gastroparesis · Dermatitis, Atopic · Pruritus · Nausea, led by 2 companies.

Drug pageTradipitant: every studyAll 21 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 13, 201819 company-led studies, 3 open or runningNext primary completion: Dec 1, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vanda Pharmaceuticals173 open or runningphase 3since Jun 13, 2018Aug 2, 2013Dec 1, 2026phase 3 · NCT07446439
Eli Lillyits history only20 open or runningphase 2since Sep 12, 2005Sep 12, 2005none ahead

Also a collaborator on its studies: Cross Research.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Vanda Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Aug 2, 2013.

  1. Nov 17, 2015Phase 1 study in Healthy VolunteersNCT02621385 · 24 enrolled · Switzerland
  2. Jan 6, 2016Phase 2 study in Dermatitis, AtopicNCT02651714 · 168 enrolled · United States
  3. Nov 15, 2016Phase 2 study in GastroparesisNCT02970968 · 152 enrolled · United States
  4. Jun 13, 2018Phase 3 study in Dermatitis, AtopicNCT03568331 · 375 enrolled · United States
  5. Nov 28, 2018Phase 2 study in Motion SicknessNCT03772340 · 126 enrolled · United States
  6. Jul 10, 2019Phase 3 study in GastroparesisNCT04028492 · 979 enrolled · United States
  7. Oct 24, 2019Phase 3 study in Dermatitis, AtopicNCT04140695 · 87 enrolled · United States
  8. Mar 26, 20202 phase 3 studiesNCT04327661, NCT04326426
  9. Apr 13, 2021Phase 2 study in Healthy VolunteerNCT04849559 · 27 enrolled · United States
  10. Mar 3, 2023Phase 3 study in Motion SicknessNCT06138613 · 705 enrolled · United States
  11. Jun 5, 2023Phase 3 study in Motion SicknessNCT05903924 · 316 enrolled · United States
  12. Apr 1, 2024Phase 3 study in GastroparesisNCT06836557 · 17 enrolled · Belgium, Germany
  13. Jan 9, 2025Phase 2 study in ObesityNCT06804603 · 124 enrolled · United States
  14. Feb 10, 2026Phase 3 study in NauseaNCT07446439 · 280 planned · United States

Ahead

  1. Dec 1, 2026Primary completion: phase 3 study in NauseaNCT07446439
  2. Sep 30, 2027Primary completion: phase 3 study in Motion SicknessNCT06138613

TargetBeta

TACR1 →read by rule
“An orally bioavailable, centrally-acting, selective, neurokinin 1 receptor (NK1-receptor; NK1R; NK-1R) antagonist ”NCIt, by rule
“Neurokinin 1 receptor antagonist”ChEMBL 37, by rule

Other programs on TACR1

ProgramCompanyFurthest phaseStudies
AprepitantruleMerckphase 427
elinzanetantruleBayerphase 324
fosnetupitantruleHelsinn Healthcarephase 32
HRS5580Jiangsu HengRui Medicinephase 22

Studies

All 17 Vanda Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07446439Nausea · United States3RecruitingDec 1, 2026280
NCT06804603Obesity · United States2CompletedOct 6, 2025124
NCT06836557Gastroparesis · Belgium, Germany3CompletedMar 30, 202617
NCT05903924Motion Sickness · United States3CompletedApr 6, 2024316
NCT06138613Motion Sickness · United States3Active, not recruitingSep 30, 2027705
NCT04849559Healthy Volunteer · United States2CompletedSep 24, 202127
NCT04327661Motion Sickness · United States3CompletedApr 1, 2023366
NCT04326426Coronavirus Infections · United States3By invitationAug 1, 2020300
NCT04140695Dermatitis, Atopic · United States3TerminatedOct 14, 202087
NCT04028492Gastroparesis · United States3CompletedFeb 21, 2025979
NCT03772340Motion Sickness · United States2CompletedJun 6, 2019126
NCT03568331Dermatitis, Atopic · United States3CompletedDec 27, 2019375
NCT02970968Gastroparesis · United States2CompletedNov 2018152
NCT02651714Dermatitis, Atopic · United States2CompletedAug 4, 2017168
NCT02621385Healthy Volunteers · Switzerland1CompletedFeb 201624
NCT02004041Pruritus · Germany2CompletedFeb 19, 201569
NCT01919944Pruritus · Switzerland1CompletedNov 201312

How it is read

Names in the registry

  • “Tradipitant”, 13 entries
  • “VLY-686”, 2 entries
  • “LY686017”, 2 entries
  • “Open Label Tradipitant”, 1 entry
  • “VLY-686 (Tradipitant)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.